HAE drug Icatibant (Firazyr) and COVID 19.
In the struggle to find new therapy's against COVID 19 a Dutch idea is to stop leakage of small bloodvessels in the lungin critically ill patients by a bradykinine inhibitor Icatibant, used in HAE patients.
Five patients are tested and the university hospital of Nijmegen is working had to set up a trial in more patients.
It's an interesting idea. And could influence the stock price of Takeda.
Icatibant (Firazyr) is a drug from Shire, indicated for use in HAE hereditary angio edema
see: https://www.preprints.org/manuscript/202004.0023/v1
for more information.
